vs
Side-by-side financial comparison of Alpha Cognition Inc. (ACOG) and Aligos Therapeutics, Inc. (ALGS). Click either name above to swap in a different company.
Alpha Cognition Inc. is the larger business by last-quarter revenue ($2.8M vs $169.0K, roughly 16.5× Aligos Therapeutics, Inc.). Alpha Cognition Inc. runs the higher net margin — -245.5% vs -11763.9%, a 11518.4% gap on every dollar of revenue.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
ACOG vs ALGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $169.0K |
| Net Profit | $-6.9M | $-19.9M |
| Gross Margin | — | — |
| Operating Margin | -283.7% | -12907.7% |
| Net Margin | -245.5% | -11763.9% |
| Revenue YoY | — | -72.1% |
| Net Profit YoY | — | 75.8% |
| EPS (diluted) | $-0.10 | $4.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $169.0K | ||
| Q3 25 | $2.8M | $741.0K | ||
| Q2 25 | $1.7M | $965.0K | ||
| Q1 25 | $2.9M | $311.0K | ||
| Q4 24 | — | $606.0K | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $694.0K |
| Q4 25 | $-6.9M | $-19.9M | ||
| Q3 25 | $-1.3M | $-31.5M | ||
| Q2 25 | $-10.5M | $-15.9M | ||
| Q1 25 | $-2.0M | $43.1M | ||
| Q4 24 | — | $-82.2M | ||
| Q3 24 | — | $-19.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-34.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 96.7% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.7% | -12907.7% | ||
| Q3 25 | -187.0% | -3827.4% | ||
| Q2 25 | -346.1% | -1924.0% | ||
| Q1 25 | -125.9% | -6187.5% | ||
| Q4 24 | — | -3393.2% | ||
| Q3 24 | — | -1610.5% | ||
| Q2 24 | — | -2489.5% | ||
| Q1 24 | — | -3176.7% |
| Q4 25 | -245.5% | -11763.9% | ||
| Q3 25 | -46.4% | -4256.0% | ||
| Q2 25 | -632.7% | -1643.8% | ||
| Q1 25 | -68.5% | 13854.7% | ||
| Q4 24 | — | -13556.1% | ||
| Q3 24 | — | -1540.7% | ||
| Q2 24 | — | 477.0% | ||
| Q1 24 | — | -5023.5% |
| Q4 25 | $-0.10 | $4.23 | ||
| Q3 25 | $-0.30 | $-3.04 | ||
| Q2 25 | $-0.65 | $-1.53 | ||
| Q1 25 | $-0.13 | $-2.11 | ||
| Q4 24 | — | $-13.10 | ||
| Q3 24 | — | $-3.07 | ||
| Q2 24 | — | $0.81 | ||
| Q1 24 | — | $-5.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.0M | $77.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $62.5M | $53.5M |
| Total Assets | $79.7M | $88.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.0M | $77.8M | ||
| Q3 25 | $35.4M | $99.1M | ||
| Q2 25 | $39.4M | $122.9M | ||
| Q1 25 | $45.5M | $137.9M | ||
| Q4 24 | — | $56.9M | ||
| Q3 24 | — | $74.9M | ||
| Q2 24 | — | $94.5M | ||
| Q1 24 | — | $112.7M |
| Q4 25 | $62.5M | $53.5M | ||
| Q3 25 | $33.9M | $71.8M | ||
| Q2 25 | $31.9M | $101.9M | ||
| Q1 25 | $40.8M | $116.4M | ||
| Q4 24 | — | $-29.0M | ||
| Q3 24 | — | $50.1M | ||
| Q2 24 | — | $67.2M | ||
| Q1 24 | — | $59.8M |
| Q4 25 | $79.7M | $88.5M | ||
| Q3 25 | $46.3M | $109.8M | ||
| Q2 25 | $45.1M | $134.7M | ||
| Q1 25 | $48.6M | $150.7M | ||
| Q4 24 | — | $70.1M | ||
| Q3 24 | — | $88.4M | ||
| Q2 24 | — | $108.8M | ||
| Q1 24 | — | $127.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.9M | $-21.7M |
| Free Cash FlowOCF − Capex | $-7.1M | — |
| FCF MarginFCF / Revenue | -252.6% | — |
| Capex IntensityCapex / Revenue | 5.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.9M | $-21.7M | ||
| Q3 25 | $-5.3M | $-24.3M | ||
| Q2 25 | $-6.1M | $-15.5M | ||
| Q1 25 | $-2.0M | $-20.9M | ||
| Q4 24 | — | $-18.4M | ||
| Q3 24 | — | $-20.1M | ||
| Q2 24 | — | $-19.5M | ||
| Q1 24 | — | $-22.7M |
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-6.1M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -252.6% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -370.9% | — | ||
| Q1 25 | -72.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
